NEW: Express access to COVID-19 vaccine record is now available.

The MyHealth.Alberta.ca Network showcases trusted, easy-to-use health and wellness resources from Alberta Health Services and Alberta-based partner organizations. The network is led by MyHealth.Alberta.ca, Alberta’s source for consumer health information. Our partners are committed to helping Albertans better manage their health and wellbeing. Health experts across Alberta make sure that the information on these sites is accurate and up-to-date. Our partners include

MyHealth.Alberta.ca Network

Main Content

Ambrisentan - Oral

Pronunciation: AM-bri-SEN-tan

Common Brand Name(s): Volibris

Important: How to Use This Information

This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

Warning

This medication must not be used during pregnancy. It may harm an unborn baby. It is important to prevent pregnancy while taking this medication and for 1 month after treatment. Female patients must use reliable birth control during treatment and for 1 month after the last dose. Ask your doctor which forms of birth control to use while taking this medication. Female patients must take a pregnancy test before starting treatment, monthly during treatment, and 1 month after the last dose. If you become pregnant or think you may be pregnant, tell your doctor right away.

For female patients to receive ambrisentan in the United States, they must understand, agree to, and carefully follow the requirements of the REMS Program for this medication. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.